IP Library Patent Application 15241958
Patent Application
App. No. 15/241,958

EPINEPHRINE-BASED OPHTHALMIC COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION AND METHODS FOR FABRICATING THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/241,958
Filed
Aug 19, 2016
Art Unit
1628
USPC
514/413
Abstract

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Claims (29)

1 - 28 . (canceled)

29 . A kit, comprising a bicameral container comprising a first section and a second section separated by a partition, wherein the first section is filled with a quantity of a lyophilized composition and the second section is filled with a quantity of sterilized water, wherein the lyophilized composition comprises

(a) one or more of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;

(b) at least one metal chelator;

(c) optionally, at least one anesthetic; and

(d) optionally, at least one non-steroid anti-inflammatory drug.

30 . The kit of claim 29 , wherein epinephrine is in the form of epinephrine hydrochlo-ride.

31 . The kit of claim 29 , wherein the metal chelator is selected from the group consisting of ethylenediaminetetraacetic acid and pharmaceutically acceptable salts thereof.

32 . The kit of claim 31 , wherein the pharmaceutically acceptable salt of ethylenediaminetetraacetic acid is disodium edetate.

33 . The kit of claim 31 , further comprising an additive selected from the group consisting of acetylcysteine, glutathione, ascorbic acid, vitamin E and a balanced salts solution.

34 . The kit of claim 29 , wherein the anesthetic is selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.

35 . The kit of claim 29 , wherein the non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.

36 . The kit of claim 29 , further optionally comprising a sulfite or preservative.

37 . The kit of claim 36 , wherein the sulfite or preservative is present at a concentration less than about 1 μM.

38 . The kit of claim 29 , wherein the anesthetic is selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.

39 . The kit of claim 30 , wherein the non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.

40 . A kit, comprising a bicameral container comprising a first section and a second section separated by a partition, wherein the first section is filled with a quantity of a lyophilized composition and the second section is filled with a carrier, wherein the lyophilized composition comprises one or more of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide.

41 . The kit of claim 40 , wherein the lyophilized composition further comprises

(a) at least one metal chelator;

(b) optionally, at least one anesthetic; and

(c) optionally, at least one non-steroid anti-inflammatory drug.

42 . The kit of claim 41 , wherein epinephrine is in the form of epinephrine hydrochloride.

43 . The kit of claim 41 , wherein the metal chelator is selected from the group consisting of ethylenediaminetetraacetic acid and pharmaceutically acceptable salts thereof.

44 . The kit of claim 41 , further comprising an additive selected from the group consisting of acetylcysteine, glutathione, ascorbic acid, vitamin E and a balanced salts solution.

45 . The kit of claim 41 , wherein the anesthetic is selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.

46 . The kit of claim 41 , wherein the non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.

47 . The kit of claim 41 , further optionally comprising a sulfite or preservative.

48 . The kit of claim 43 , wherein the anesthetic is selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.

49 . The kit of claim 43 , wherein the non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded May 7, 2021
From: SWK FUNDING LLC
To: HARROW IP, LLC
Reel/Frame 056174/0332 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 21, 2019
From: HARROW IP, LLC
To: SWK FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 051079/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2019
From: IMPRIMIS PHARMACEUTICALS, INC.
To: HARROW IP, LLC
Reel/Frame 050985/0969 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 19, 2017
From: IMPRIMIS PHARMACEUTICALS, INC.
To: SWK FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 043258/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2016
From: KAROLCHYK, JOHN SCOTT; BAUM, MARK L.
To: IMPRIMIS PHARMACEUTICALS, INC.
Reel/Frame 039954/0711 →